Skip to main content

Table 1 Treatment Groups in Patients with Mucosal Leishmaniasis (Peru)

From: Consultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasis

Cohort

N

Treatment

Timing of Treatment

   

Study Injections

Pentavalent Antimony (Sb5+)

# 1

12

4

5 μg Leish-111f in 25 μg MPL-SE + Sb5+

Placebo (saline) + Sb5+

Day 0, Day 28 and Day 56

SSC1

# 2*

12

4

10 μg Leish-111f in 25 μg MPL-SE + Sb5+

Placebo (saline) + Sb5+

Day 0, Day 28 and Day 56

SSC1

# 3**

12

4

20 μg Leish-111f in 25 μg MPL-SE + Sb5+

Placebo (saline) + Sb5+

Day 0, Day 28 and Day 56

SSC1

  1. 1SSC = Standard single cycle: 28 days of pentavalent antimony (20 mg/kg IV once daily) starting on Day 0.
  2. Sequential enrollment of cohorts: * = after Day 84 of cohort 1; ** = after Day 84 of cohort 2.
Back to article page

Kinetoplastid Biology and Disease

ISSN: 1475-9292